The coronary stent was chosen to be the first Chinese national volume-based procurement of high-value medical supplies in 2020，of which policies and results are summarized in this article. There has had a huge impact on the percutaneous coronary intervention（PCI）market，and has shaken the market structure formed in the past two decades. However，the Chinese PCI market is still far away from maturity，and there is still a large growing number of surgical cases and medical product innovation. While reducing the medical costs of patients，the loss of market size will be made up for by more surgeries and charging for better clinical services. After analyzing the basic Chinese PCI statistics，this article provides some references and insights for developing the PCI market from three aspects，which are the increase in patient size，the popularization of clinical strategies for precise medical treatment of PCI，and the innovation of implant-free treatment. At last，the volume-based procurement will guide the innovation and development of outstanding domestic medical device manufacturers，promote technological upgrades of relevant industries，and provide more high-quality clinical and surgical strategies for patients with coronary heart disease.